CC
SRPT icon

Carlson Capital’s Sarepta Therapeutics SRPT Stock Holding History

Carlson Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,845,702
Closed -$54.6M – 289
2017
Q1 		$54.6M Sell
1,845,702
-357,063
-16% -$11.1M 0.69% 41
2016
Q4 		$60.4M Buy
+2,202,765
New +$88.5M 0.72% 35

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Carlson Capital's SRPT Position: Q2 2017 in Review

Carlson Capital sold out of Sarepta Therapeutics (SRPT) in Q2 2017, closing a stake of 1,845,702 shares — an estimated $54.6M sold.

Carlson Capital first reported a position in SRPT in Q4 2016 and held it in 2 quarters. The position peaked at $60.4M in Q4 2016. 190 funds tracked by Wall St. Rank hold SRPT as of Q2 2017.

  • Carlson Capital reported no remaining Sarepta Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Carlson Capital sold 1,845,702 Sarepta Therapeutics shares in Q2 2017, an estimated $54.6M.
  • Carlson Capital first reported a position in Sarepta Therapeutics in Q4 2016 and held it in 2 quarters.
  • Carlson Capital's Sarepta Therapeutics position peaked at $60.4M in Q4 2016.
  • 190 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2017.

Based on Carlson Capital's 13F filing for Q2 2017, filed 14 Aug 2017.